The Cancer Immunotherapy segment focuses on the development of personalized neoantigen-based immunotherapies, primarily through the GRANITE platform. This involves identifying and targeting unique neoantigens present on cancer cells to stimulate an immune response. Research and development activities include identifying neoantigen targets, designing and manufacturing personalized cancer vaccines, and conducting clinical trials to evaluate safety and efficacy. Technologies employed include next-generation sequencing, machine learning for neoantigen prediction, and advanced vaccine manufacturing processes. The therapeutic areas covered include solid tumors such as metastatic non-small cell lung cancer, gastroesophageal, bladder, and colorectal cancers. The goal is to improve patient outcomes by providing a targeted and effective treatment option for various cancers. Market positioning is based on the potential for personalized cancer vaccines to provide a more effective and less toxic treatment option compared to traditional therapies. Competitive advantages include the use of a proprietary platform for neoantigen identification and vaccine design. Future opportunities include expanding the platform to treat additional cancer types and exploring combination therapies. Clinical trials are a key aspect of this segment, with regulatory approvals from relevant health authorities being essential for commercialization. Partnerships with research institutions and pharmaceutical companies are crucial for advancing clinical development and commercialization.

This segment is dedicated to developing vaccine platforms for infectious diseases, with a primary focus on the CORAL platform for SARS-CoV-2 variants and the SLATE platform for shared neoantigen-positive tumors. Research and development activities include identifying and selecting relevant viral antigens, designing and manufacturing vaccine candidates, and conducting preclinical and clinical studies to assess safety and efficacy. Technologies used include self-amplifying mRNA (samRNA) technology, advanced immunology techniques, and vaccine formulation expertise. The therapeutic areas covered include protection against SARS-CoV-2 variants and the treatment of common solid tumors. The patient impact is aimed at providing broad and durable immunity against emerging viral threats and offering off-the-shelf immunotherapy options for various cancers. Market positioning is based on the potential to provide effective and accessible vaccines and immunotherapies. Competitive advantages include the use of innovative vaccine platforms and the ability to rapidly adapt to emerging viral variants. Future opportunities include expanding the platform to address other infectious diseases and exploring combination therapies. Regulatory approvals and clinical trial success are critical for commercialization. Partnerships with government agencies, research institutions, and pharmaceutical companies are essential for advancing clinical development and commercialization.